Repligen SVP R&D granted options and RSUs

Repligen Corporation Senior VP of R&D Ralf Kuriyel received new equity awards in the form of stock options and restricted stock units.

Rhea-AI Filing Summary

Repligen Corporation Senior VP of R&D Ralf Kuriyel received new equity awards in the form of stock options and restricted stock units. He was granted 5,669 stock options to buy Common Stock at an exercise price of $141.91 per share, expiring on March 5, 2036. One third of these options will vest and become exercisable on each of March 5, 2027, March 5, 2028, and March 5, 2029. He also received 5,284 restricted stock units, each representing one share of Common Stock, vesting in equal annual installments over three years starting on the first anniversary of the grant date. After the restricted stock unit grant, his direct Common Stock holdings increased to 20,062 shares.

Insider Trade Summary

Grant/Award: 10,953 shares

Grant/Award 2 txns

Insider KURIYEL RALF

Role Senior VP, R&D

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,669	$0.00	$0.00
Grant/Award	Common Stock	5,284	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 5,669 contracts (Direct); Common Stock — 20,062 shares (Direct)

Footnotes (2)

1. F1. Mr. Kuriyel was awarded 5,284 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
2. F2. One third of the stock options will vest and become exercisable annually on March 5, 2027, March 5, 2028, and March 5, 2029.

FAQ

What equity awards did Ralf Kuriyel receive from Repligen (RGEN)?

Ralf Kuriyel received 5,669 stock options and 5,284 restricted stock units. The stock options allow him to buy Common Stock at $141.91 per share, while each restricted stock unit represents one share of Repligen Common Stock delivered upon vesting.

How do the new Repligen (RGEN) stock options for Ralf Kuriyel vest?

The 5,669 stock options vest in three equal annual installments. One third becomes exercisable on each of March 5, 2027, March 5, 2028, and March 5, 2029, giving a staged vesting schedule tied to continued service.

What is the vesting schedule for Ralf Kuriyel’s restricted stock units at Repligen (RGEN)?

The 5,284 restricted stock units vest in equal annual installments over three years. Vesting begins on the first anniversary of the grant date, and each vested unit is settled by delivering one share of Repligen Common Stock.

What exercise price and expiration date apply to Ralf Kuriyel’s Repligen (RGEN) stock options?

The granted stock options carry an exercise price of $141.91 per share and expire on March 5, 2036. They only become exercisable as they vest in one-third increments during 2027, 2028, and 2029.

How many Repligen (RGEN) Common Stock shares does Ralf Kuriyel hold after these grants?

Following the award of 5,284 restricted stock units reported as Common Stock, Ralf Kuriyel directly holds 20,062 shares of Repligen Common Stock. This reflects his updated direct ownership position after the latest equity compensation grants.

Are Ralf Kuriyel’s restricted stock units in Repligen (RGEN) settled in cash or shares?

The restricted stock units may be settled only by delivering shares of Repligen Common Stock. Each restricted stock unit represents a contingent right to receive one share when the vesting conditions are satisfied over the three-year schedule.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/23/2026 - 12:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KURIYEL RALF

(Last) (First) (Middle)

C/O REPLIGEN CORPORATION

41 SEYON ST., BLDG 1, STE 100

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REPLIGEN CORP [ RGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior VP, R&D

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		A		5,284(1)	A	$0	20,062	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$141.91	03/05/2026		A		5,669		(2)	03/05/2036	Common Stock	5,669	$0	5,669	D

Explanation of Responses:

1. Mr. Kuriyel was awarded 5,284 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

2. One third of the stock options will vest and become exercisable annually on March 5, 2027, March 5, 2028, and March 5, 2029.

	/s/ Jennifer Carmichael (Attorney in Fact)	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)